Literature DB >> 18192508

Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

Syed-Rehan A Hussain1, David M Lucas, Amy J Johnson, Thomas S Lin, Alan P Bakaletz, Vinh X Dang, Serge Viatchenko-Karpinski, Amy S Ruppert, John C Byrd, Periannan Kuppusamy, Elliott D Crouser, Michael R Grever.   

Abstract

Effective administration of flavopiridol in advanced-stage chronic lymphocytic leukemia (CLL) is often associated with early biochemical evidence of tumor cell lysis. Previous work using other cell types showed that flavopiridol impacts mitochondria, and in CLL cells flavopiridol down-regulates the mitochondrial protein Mcl-1. We therefore investigated mitochondrial structure and function in flavopiridol-treated CLL patient cells and in the lymphoblastic cell line 697 using concentrations and times at which tumor lysis is observed in treated patients. Mitochondrial membrane depolarization was detected in flavopiridol-treated CLL cells by 6 hours, well before the onset of cell death. Flavopiridol-induced mitochondrial depolarization was not blocked by caspase inhibitors or by the calcium chelator EGTA, but was reduced by Bcl-2 overexpression. Intracellular calcium mobilization was noted at early time points using fluorescence microscopy. Furthermore, electron paramagnetic resonance oximetry showed a gradual but significant reduction in cellular oxygen consumption rate by 6 hours, corresponding with ultrastructural mitochondrial damage detected by electron microscopy. These observations suggest that in CLL and 697 cells, flavopiridol mediates its cytotoxic effects via induction of the mitochondrial permeability transition and changes in intracellular calcium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192508      PMCID: PMC2265456          DOI: 10.1182/blood-2007-10-115733

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

Authors:  Roberto R Rosato; Jorge A Almenara; Leanne Cartee; Vicki Betts; Srikumar P Chellappan; Steven Grant
Journal:  Mol Cancer Ther       Date:  2002-02       Impact factor: 6.261

Review 2.  Death receptors leave a caspase footprint that Smacs of XIAP.

Authors:  S B Bratton; G M Cohen
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

3.  Modulation of the activity of calcium-activated neutral proteases (calpains) in chronic lymphocytic leukemia (B-CLL) cells.

Authors:  Jacek M Witkowski; Emilia Zmuda-Trzebiatowska; Jakub M Swiercz; Miroslawa Cichorek; Hanna Ciepluch; Krzysztof Lewandowski; Ewa Bryl; Andrzej Hellmann
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

4.  Correlated three-dimensional light and electron microscopy reveals transformation of mitochondria during apoptosis.

Authors:  Mei G Sun; James Williams; Cristina Munoz-Pinedo; Guy A Perkins; Joshua M Brown; Mark H Ellisman; Douglas R Green; Terrence G Frey
Journal:  Nat Cell Biol       Date:  2007-08-26       Impact factor: 28.824

5.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

Authors:  Ivana Gojo; Bin Zhang; Robert G Fenton
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.

Authors:  Michelle Alonso; Cristina Tamasdan; Douglas C Miller; Elizabeth W Newcomb
Journal:  Mol Cancer Ther       Date:  2003-02       Impact factor: 6.261

7.  Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor.

Authors:  Elizabeth W Newcomb; Cristina Tamasdan; Yolanda Entzminger; Judith Alonso; David Friedlander; Diana Crisan; Douglas C Miller; David Zagzag
Journal:  Cell Cycle       Date:  2003 May-Jun       Impact factor: 4.534

8.  Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.

Authors:  Julie Litz; Patricia Carlson; G Sakuntala Warshamana-Greene; Steven Grant; Geoffrey W Krystal
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

9.  Pore formation and uncoupling initiate a Ca2+-independent degradation of mitochondrial phospholipids.

Authors:  Kimberly M Broekemeier; James R Iben; Emily G LeVan; Elliott D Crouser; Douglas R Pfeiffer
Journal:  Biochemistry       Date:  2002-06-18       Impact factor: 3.162

10.  Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors.

Authors:  Chi Li; Casey J Fox; Stephen R Master; Vytautas P Bindokas; Lewis A Chodosh; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-12       Impact factor: 11.205

View more
  27 in total

1.  ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

Authors:  Emilia Mahoney; David M Lucas; Sneha V Gupta; Amy J Wagner; Sarah E M Herman; Lisa L Smith; Yuh-Ying Yeh; Leslie Andritsos; Jeffrey A Jones; Joseph M Flynn; Kristie A Blum; Xiaoli Zhang; Amy Lehman; Hui Kong; Metin Gurcan; Michael R Grever; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

Review 2.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

3.  Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

Authors:  Kami Maddocks; Lai Wei; Darlene Rozewski; Yao Jiang; Yuan Zhao; Mikhil Adusumilli; William E Pierceall; Camille Doykin; Michael H Cardone; Jeffrey A Jones; Joseph Flynn; Leslie A Andritsos; Michael R Grever; John C Byrd; Amy J Johnson; Mitch A Phelps; Kristie A Blum
Journal:  Am J Hematol       Date:  2015-02-25       Impact factor: 10.047

4.  Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.

Authors:  Darcy J P Bates; Bethany L Salerni; Christopher H Lowrey; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

5.  The calcium-sensing receptor is necessary for the rapid development of hypercalcemia in human lung squamous cell carcinoma.

Authors:  Gwendolen Lorch; Serge Viatchenko-Karpinski; Hsiang-Ting Ho; Wessel P Dirksen; Ramiro E Toribio; John Foley; Sandor Györke; Thomas J Rosol
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

6.  Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.

Authors:  William Blum; Mitch A Phelps; Rebecca B Klisovic; Darlene M Rozewski; Wenjun Ni; Katie A Albanese; Brad Rovin; Cheryl Kefauver; Steven M Devine; David M Lucas; Amy Johnson; Larry J Schaaf; John C Byrd; Guido Marcucci; Michael R Grever
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

7.  Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

Authors:  Velasco Cimica; Melissa E Smith; Zhikai Zhang; Deepti Mathur; Sridhar Mani; Ganjam V Kalpana
Journal:  BMC Cancer       Date:  2010-11-19       Impact factor: 4.430

Review 8.  Emerging drug profile: cyclin-dependent kinase inhibitors.

Authors:  James S Blachly; John C Byrd
Journal:  Leuk Lymphoma       Date:  2013-07-29

9.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

10.  Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.

Authors:  Daniel R Premkumar; Esther P Jane; Swetha Thambireddy; Philip A Sutera; Jonathon M Cavaleri; Ian F Pollack
Journal:  Mol Carcinog       Date:  2017-12-30       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.